Dissolution Profile Similarity (f₂) Calculator
- Purpose: This calculator evaluates similarity between Test Product and Reference Product dissolution profiles using f₂ (Similarity Factor) and f₁ (Difference Factor) as per regulatory requirements.
- Enter Optional Sections details:
- Product Detail: For documentation and reporting.
- Dissolution Method Detail: To capture experimental conditions.
- Enter Dissolution Profile Data:
- Provide Time Points (min) (excluding 0).
- Enter Reference (prechange) Product (% drug dissolved).
- Enter Test (postchange) Product (% drug dissolved).
- A minimum of three (03) common time points (excluding zero) is required for calculation.
- Confirm variability criteria compliance.
- Click Calculate to compute f₂ and f₁ values with interpretation.
- Click Show Detailed Calculation to review step-by-step calculations.
- Use Print / Save as PDF to generate a report. Always review the printed report for correctness before use.
-
Methodology & Conditions
- Model-Independent: Profiles are compared directly at each time point without kinetic modeling.
- Identical Conditions: Test and Reference must share the same apparatus, medium, agitation speed, and temperature.
- Sampling Time Points: Must be identical for both (e.g., 5, 10, 15, 30, 45, 60 min) and cover the full profile including early, intermediate, and later stages of dissolution.
- Plateau Condition: If 85% dissolution is not reached, include time points until a plateau (asymptotic release) is observed.
- Continuity: Do not skip intermediate time points between selected sampling intervals.
- Early Sampling: For rapidly dissolving products, where complete dissolution is within 30 minutes, generation of an adequate profile by sampling at 5- or 10-minute intervals may be necessary.
-
Data Requirements
- Sample Size: Mean data from twelve (12) dosage units per time point for each formulation.
- Minimum Data: At least 3 time points (excluding zero) are required.
- Variability Criteria: % RSD (relative standard deviation) / % CV (coefficient of variation) must not exceed 20% at the first/earlier time point and 10% at all subsequent time points.
- ICH M13B Criterion: For additional-strength biowaivers, conventional f2 assessment applies when the standard deviation (SD) is ≤8% at all time points for both the additional-strength and biobatch-strength profiles.
-
Evaluation & Constraints
- The 85% Rule: Only one time point is included after ≥85% dissolution for any of the formulations; subsequent points are excluded automatically.
- Very Rapid Dissolution: If Test & Reference products both reach ≥85% dissolution in ≤15 min, the profiles may be considered similar without further mathematical evaluation.
- Similarity factor (f₂): values should be close to 100 and f₂ ≥ 50 (range 50–100) indicates similarity between profiles.
- Difference factor (f₁): values should be close to 0 and f₁ ≤ 15 (range 0–15) indicates acceptable difference.
-
Applicability
- Applicable to oral solid dosage forms (e.g., tablets and capsules).
- Suitable for Immediate Release (IR) and Modified Release (MR) formulations.
📖 How to Use Calculator
⚖️ Important Notes
| Time (min) | Reference Product (mean % drug dissolved) | Test Product (mean % drug dissolved) |
|---|
📖 Continue Exploring
This page includes a comprehensive guide on dissolution profile comparison, a detailed FAQ section, and links to additional pharmaceutical calculators. Use the quick navigation below to jump directly to any section.
Dissolution Profile Similarity (f₂) Calculator – Guide
What is Dissolution?
Dissolution is the physical process by which a solid substance enters a solvent to yield a solution. In pharmacy and biopharmaceutics, dissolution is defined as the process by which a solid drug substance dissolves into a medium per unit of time (rate) and reaches a total cumulative amount of dissolved drug (extent) under standardized conditions.
What is Dissolution Profile?
A dissolution profile is a graphical plot or dataset that shows the cumulative amount of a drug substance released from a dosage form into a liquid medium over specific time intervals. It maps the entire timeline of how a drug dissolves from the moment it contacts a liquid until it is completely released.
What is Dissolution Profile Similarity (f₂) Factor?
The dissolution profile Similarity Factor (f₂) is a model-independent mathematical approach used in the pharmaceutical industry to compare the dissolution profiles of a Test Product (e.g., a generic drug or a post-modification batch) and a Reference Product (e.g., the innovator drug or a pre-modification batch). The f₂ approach compares the percentage of drug dissolved at each common sampling time point and provides a single numerical value describing the similarity between the two profiles. It is widely accepted by regulatory agencies for assessing whether two products exhibit similar drug release characteristics under identical dissolution conditions.
Why is Dissolution Profile Comparison Important?
Dissolution profile comparison plays a critical role in pharmaceutical development and regulatory submissions. It helps demonstrate that formulation or manufacturing changes do not significantly alter drug release performance. Demonstrating dissolution profile similarity can help justify product equivalence and support regulatory submissions.
Dissolution profile comparison may be required for:
- Post-approval changes
- Scale-up and post-approval changes (SUPAC)
- Site transfer activities
- Formulation optimization studies
- Generic drug development
- Technology transfer activities
- Stability assessment studies
- Comparative development batches
- Regulatory Biowaivers
- Multiple Strengths
Understanding Similarity Factor (f₂)
The similarity factor (f₂) is a logarithmic reciprocal square root transformation of the sum of squared errors between the Test and Reference dissolution profiles.
- f₂: The similarity factor value
- n: The total number of dissolution time points sampled
- Rt: The cumulative percentage of drug dissolved from the Reference formulation at time point t
- Tt: The cumulative percentage of drug dissolved from the Test formulation at time point t
- log: The base-10 logarithm
Interpretation of f₂ Values
| f₂ Value Range | Profile Interpretation |
|---|---|
| 50 – 100 | Similar dissolution profiles (acceptable from a regulatory perspective) |
| < 50 | Dissimilar dissolution profiles |
In practice, values between 50 and 100 indicate that the average difference between the two profiles is sufficiently small and generally acceptable from a regulatory perspective.
Understanding Difference Factor (f₁)
The difference factor (f₁) calculates the percent error or difference between the two curves across all time points. It focuses on the relative error between the Test and Reference profiles.
- f₁: The difference factor value
- n: The total number of dissolution time points sampled
- Rt: The cumulative percentage of drug dissolved from the Reference formulation at time point t
- Tt: The cumulative percentage of drug dissolved from the Test formulation at time point t
- |Rt - Tt|: The absolute difference (always positive) between the two profiles at time point t
Interpretation of f₁ Values
| f₁ Value Range | Profile Interpretation |
|---|---|
| 0 – 15 | Acceptable difference (profiles match closely) |
| > 15 | Potentially significant difference |
A lower f₁ value indicates closer agreement between the dissolution profiles.
Regulatory Expectations for f₂ Evaluation
Regulatory authorities commonly recommend the use of f₂ for comparing dissolution profiles when:
- At least 12 dosage units are evaluated.
- A minimum of three common time points are available.
- Dissolution conditions are identical.
- Variability criteria are met.
- Sampling points adequately characterize the release profile.
Special consideration should be given to rapidly dissolving products and profiles where more than 85% drug release occurs early in the study.
When is f₂ Applicable?
The f₂ approach is commonly used for:
- Immediate Release (IR) Products: Comparison of formulation changes, manufacturing changes, and generic product development.
- Modified Release (MR) Products: Comparison of release characteristics between development batches and commercial products.
- Technology Transfer Activities: Verification that the receiving manufacturing site produces a product equivalent to the sending site.
- Post-Approval Changes: Assessment of the impact of formulation, process, equipment, or site changes.
When f₂ is NOT Applicable or May Be Waived?
The similarity factor (f₂) approach is not applicable or may be waived under the following circumstances:
- Very Rapid Dissolution: If both the Test and Reference products achieve ≥85% drug dissolution within 15 minutes, the profiles may be considered similar without further mathematical evaluation.
- High Data Variability: When the %RSD (Relative Standard Deviation) or %CV (Coefficient of Variation) exceeds 20% at the earliest sampling time point or 10% at subsequent time points, the standard f₂ calculation may not be statistically reliable. In such cases, alternative statistical approaches such as bootstrap confidence interval methods or Mahalanobis distance analysis should be considered.
- ICH M13B High Variability: For additional-strength biowaivers, if SD (Standard Deviation) >8% at any time point, the bootstrap approach should be used as specified in ICH M13B. Dissolution similarity is demonstrated when the lower bound of the two-sided 90% bootstrapped confidence interval for the similarity factor is ≥46 and the median f₂ is ≥50.
- Insufficient Sampling Points: The f₂ calculation requires at least three common sampling time points (excluding the zero time point). Datasets with fewer than three matching time points are not suitable for f₂ evaluation.
- Fundamentally Different Dosage Forms or Release Mechanisms: The f₂ approach should not be used to compare products with substantially different release characteristics or dosage forms, such as an immediate-release formulation versus an extended-release formulation.
Example of Dissolution Profile Comparison Using the Calculator
Consider a Test product and a Reference product evaluated at common dissolution sampling time points of 10, 15, 20, and 30 minutes. The mean percentage of drug dissolved at each time point is entered into the calculator.
Based on the provided data, the calculator automatically determines:
- Difference Factor (f₁)
- Similarity Factor (f₂)
- Interpretation of the results
The calculated f₁ and f₂ values are then used to assess whether the dissolution profiles of the Test and Reference products can be considered similar according to established regulatory acceptance criteria.
Common Mistakes During f₂ Evaluation
The following structural issues commonly lead to inappropriate, inaccurate, or unreliable dissolution profile comparisons:
- Using different sampling time points for the Test and Reference products
- Including fewer than three common sampling time points (excluding the zero time point)
- Ignoring variability limits specified for f₂ calculations
- Including an excessive number of sampling points after both products have reached 85% dissolution
- Comparing dissolution profiles generated under different dissolution test conditions (e.g., apparatus, medium, agitation speed, or temperature)
- Using individual unit dissolution data instead of mean dissolution profile values
- Failing to adequately evaluate the plateau region when relevant to the product’s release characteristics
Careful study design, appropriate sampling schedules, and adherence to regulatory recommendations are essential for obtaining scientifically meaningful and regulatory-acceptable f₂ results.
References
- U.S. Food and Drug Administration (FDA). Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms; Center for Drug Evaluation and Research (CDER): Silver Spring, MD, USA, 1997.
- European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/ Corr); EMA: London, UK, 2010.
- Health Canada. Guidance Document: Use of a Foreign-Sourced Reference Product as a Canadian Reference Product; Health Canada: Ottawa, ON, Canada, 2018.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). M9: Biopharmaceutics Classification System-Based Biowaivers; ICH Harmonised Guideline; ICH: Geneva, Switzerland, 2019.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). M13B: Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver; ICH Harmonised Guideline; ICH: Geneva, Switzerland, 2026.
- Moore, J.W.; Flanner, H.H. Mathematical comparison of dissolution profiles. Pharm. Technol. 1996, 20, 64–74.
- Shah, V.P.; Tsong, Y.; Sathe, P.; Liu, J.P. In vitro dissolution profile comparison—statistics and analysis of the similarity factor, f₂. Pharm. Res. 1998, 15, 889–896.
Frequently Asked Questions
What are the minimum data inputs required to run a calculation?
You must enter at least three common sampling time points (excluding zero), along with the corresponding mean percentage of drug dissolved for both the Reference (pre-change) and Test (post-change) products.
How can I verify the mathematical steps used by the tool?
Click the Show Detailed Calculation button after running your data to review the step-by-step breakdown of the formula.
Can I skip intermediate time points when entering data into the calculator?
No. The guidelines require complete continuity; you must not skip any intermediate time points between your selected sampling intervals.
Is time point zero (0 minutes) included in the minimum of three time points?
No. The minimum requirement of three common time points strictly excludes the baseline zero time point.
How does the calculator handle data points collected after the drug has mostly dissolved?
The calculator applies the 85% Rule. It automatically includes only one time point after any formulation reaches ≥85% dissolution and excludes all subsequent points.
How frequently should I collect samples for a rapidly dissolving drug?
For products that dissolve completely within 30 minutes, you should sample early at 5- or 10-minute intervals to map an adequate profile.
Which specific test parameters must remain completely identical between the Test and Reference batches?
Both batches must share the exact same laboratory apparatus type, dissolution medium, agitation speed (RPM), and fluid temperature.
How many tablets or capsules do I need to test to get my profile data?
Your input values must represent the mean data derived from twelve (12) individual dosage units per time point for each formulation.
What should I do if the drug does not reach 85% dissolution during testing?
You must continue sampling and include time points until a clear plateau (asymptotic release) is observed in the dissolution profile.
What are the acceptable limits for data variability?
The %RSD (Relative Standard Deviation) or %CV (Coefficient of Variation) must not exceed 20% at the first or earliest time point, and it must stay under 10% at all subsequent time points. For additional-strength biowaivers, as per ICH M13B, the SD (Standard Deviation) should be ≤8% at all time points for both the additional-strength and biobatch-strength profiles.
In simple terms, what do the f₁ and f₂ formulas actually measure?
The f₁ formula calculates the average percent difference between the two curves at each moment, focusing on the gap between them. The f₂ formula uses squared differences to penalize larger gaps more heavily, converting the final result into a score from 0 to 100 to prove mathematical similarity.
What is the ideal target value for the Difference factor (f₁), and why is it calculated?
The f₁ value should ideally be as close to 0 as possible, indicating no meaningful difference between the profiles.
The f₁ value provides additional information regarding the percentage difference between the two dissolution profiles and complements the f₂ assessment.
Do I still need to evaluate the f₂ score if my product qualifies as "very rapidly dissolving"?
No. Under the Very Rapid Dissolution rule, If both the Test and Reference products achieve ≥85% drug dissolution within 15 minutes, the profiles may be considered similar without further mathematical evaluation.
Can I generate a record or report of my calculation results?
Yes. You can use the Print / Save as PDF option to generate a comprehensive report for your files.
Is there a quality check step recommended after exporting my report?
Yes. You should always manually review the printed or saved PDF report for correctness before using it for formal documentation.
Other Pharmaceutical Calculators
Streamline Your Operations with Advanced Pharmaceutical Scaling & Compliance Tools:
Transitioning from laboratory-scale formulation to high-throughput commercial batches requires flawless precision across every mathematical variable. To eliminate calculation bottlenecks, mitigate cross-contamination risks, and expedite technology transfers, explore our suite of interconnected pharmaceutical development and manufacturing calculators.